Adele Gulfo serves as Mylan’s Head of Global Commercial Development, and Director of Bemis, Inc. (BMS) serving on the company’s Audit Committee. A member of Mylan’s Executive Team, she is responsible for ensuring markets are optimally prepared to launch and grow pipeline assets, including Respiratory, Diabetes, Infectious Disease, and Biosimilars across Immunology and Oncology
Previously, Gulfo served as President and General Manager of Pfizer’s U.S. Primary Care Business Unit, where she was responsible for leading over 5,000 people and generating ~$13 billion in revenue.
Prior to that, Gulfo was responsible for the launch and commercial success of LIPITOR®, the world’s best-selling medicine. She was recognized for her leadership in marketing and medical education campaigns that helped to establish the significance of lowering cholesterol in preventing and managing heart disease.
Gulfo also served as Pfizer’s President of Latin America. She led a team of over 4,000 colleagues across two dozen countries, and grew revenue to more than $3B while delivering double-digit bottom-line growth.
Prior to joining Pfizer, Gulfo led AstraZeneca’s multi-billion dollar cardiovascular business. Among her achievements she launched Crestor® with a significantly differentiated clinical development program, putting it on a blockbuster path. She then became Vice President of Business Development, Innovation and Design for Launch, where she focused on growing AstraZeneca’s business across multiple therapeutic areas including, Oncology, GI and Respiratory.
Trained as a scientist with experience in both operational and strategic roles, Gulfo has been awarded five U.S. patents for patient adherence packaging. She serves as an Innovation Advisor to PARTNERS Healthcare, the $10 billion Boston-based healthcare system, and Cleveland Clinic’s Innovation Center. She also serves on the Board of Directors for Volunteers of America (VOA) – Greater New York, is an advisor for the Healthcare Business Women’s Association (HBA), and is a member of the Committee of 200 (C200), the world’s premier women’s business leadership organization.
Among many honors, she is especially proud of receiving the 2015 Pinnacle in Leadership Award for STEM from the Girl Scouts of Greater New York, and being honored as one of the top 100 Corporate Leaders in STEM. In 2014, she was inducted into the Pinnacle Society at Fairleigh Dickinson University and was honored at the Executive Women of New Jersey’s “Salute to the Policy Makers.” She received the 2012 C200 Luminary Award for Corporate Innovation, and the 2013 Oracle Award by Springboard Enterprises, which is bestowed by an expert network of innovators and investors dedicated to building high-growth technology-oriented companies led by women.
She frequently speaks at leading industry and business conferences including The Wall Street Journal’s “Women in the Economy”, and has been featured in Fortune, Forbes, BusinessWeek, The International Consortium for Executive Development Research (ICEDR) and The Wall Street Journal.
She holds a bachelor’s degree in biology from Seton Hall University and an MBA from Fairleigh Dickinson University. She studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey.